Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. - sprookjes - yvandenbroek - TriplyDB

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

http://www.wikidata.org/entity/Q27852316

about

Update in lung cancer and mesothelioma 2012 Crizotinib resistance: implications for therapeutic strategies Crizotinib: from discovery to accelerated development to front-line treatment Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection Targeted therapies and immunotherapy in non-small-cell lung cancer Tackling ALK in non-small cell lung cancer: the role of novel inhibitors New targeted treatments for non-small-cell lung cancer - role of nivolumab Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer The role of pembrolizumab in the treatment of advanced non-small cell lung cancer Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs ALK inhibitors in non-small cell lung cancer: the latest evidence and developments Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Lung cancer biomarkers, targeted therapies and clinical assays c-Met as a Target for Personalized Therapy Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib Translating cancer genomes and transcriptomes for precision oncology Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group The distinctive nature of adenocarcinoma of the lung Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds Advances in Diagnosis and Treatment of Multiple Primary Lung Cancer Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review Patterns of Chromosomal Aberrations in Solid Tumors Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses Novel targeted agents for the treatment of lung cancer in China The Evolution of Therapies in Non-Small Cell Lung Cancer Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy Medical management of lung cancer: Experience in China Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough

P2860

5dcaf9fdfa50aaa467325765f68c752f58b05765

P248

Q24619675-DF038A10-207D-4D73-BD43-87CC7763461A Q26738381-4225E653-8C3A-437F-9138-BFC6E895AED0 Q26738385-5E292BD7-EB4B-4081-9CA0-9CAEF7322136 Q26738860-197A0513-58C4-442C-AD0E-BAC4574D91E0 Q26738986-BFA3771E-FB86-40E0-907C-0A2CC376A3AE Q26740329-DC4DD1B6-552D-4024-8285-85533723EEEE Q26740988-4A070ECA-781E-42AA-BA68-8801CD7BB9A4 Q26741009-95C596C7-04E2-40EC-B332-8F6D9DB7FF6F Q26741998-A8A8C6D7-6382-4339-9357-28CCCFFD1049 Q26744076-C67B4A42-6887-4DA4-BD42-DB1306BD0347 Q26745427-0B8507CB-4DD1-4133-A8C1-35C189634699 Q26767182-0CB3F7E3-5952-4A31-B9BC-3C1DDD8AC830 Q26769659-A55181F2-6B4F-498A-9CC3-9B2F6D85C366 Q26769879-AD213274-17A8-4FE3-AA38-4A3CF8EEFAA7 Q26774625-1847E636-3B82-48AB-8BF8-CA5162A84199 Q26775347-ACB88CC6-DC8A-414E-9E63-663C0FAA39B4 Q26775388-7A9A2AC8-A8E1-4B46-B036-9A60891F830E Q26775394-CA09A042-E677-476C-AE55-373134F87CE2 Q26775396-455F95A8-A2EC-4931-B44D-A42BFE5D4239 Q26775483-BA9EA4D6-D945-45C7-88A0-4FE8450B7035 Q26775817-34C70D29-7F89-48C2-9459-AFE84A1ACBC5 Q26777081-5D4C27F9-DFC4-4696-A0D3-1CBF1E14E256 Q26777427-06A78D79-BCB2-4680-881F-0CACC8286AAE Q26778500-2D48EF35-8814-47AD-AD69-849271B712B7 Q26780457-943ECEE0-71FB-4CFC-96AC-4344C613C23C Q26781159-1C6D38D4-56CB-4215-9878-DDB8480C071E Q26781273-C230EAC5-5174-4C09-9F08-8876B5B623DB Q26781662-43D1FE81-329A-4142-9266-9121D5F639F0 Q26781686-B7E8FB22-1AF3-4919-A706-A8B07E79B15B Q26781810-63D23BCB-FD5E-4547-B010-390E0093B85D Q26784085-CBE50FB5-3074-42B2-A032-069E428E5C70 Q26784298-CD64FA9E-B196-4D54-BBF9-09D6D14D9B2A Q26785713-AE3BAB4B-5254-462A-8F41-B922249BE39B Q26786127-F7808E5D-C846-4A4C-BED0-D4162E35CDE9 Q26786243-6204B834-9254-4E57-BF22-EFB81D8B8F60 Q26786580-0728C7CD-F244-4B9E-90E4-933697B967D4 Q26786932-A1693F9E-871D-43F9-B941-E51F61672474 Q26795555-92C05DCA-F1B0-41F8-AADE-CDCEEA78CB45 Q26798257-FEAC10EF-3537-4CC8-B8BF-069CD9E8BD87 Q26799467-8F5A7DF4-1926-4BF9-83E5-A1E7F2B4210B

P2860

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

http://www.wikidata.org/entity/Q27852316

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

@ast

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

@en

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

@nl

type

label

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

@ast

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

@en

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

@nl

prefLabel

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

@ast

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

@en

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

@nl

P1433

Q27852316-351693BE-3570-48EA-83EA-65B725638094

P1476

Q27852316-A3F11F0A-52B2-483D-9CDB-224D0117C9BE

P2093

Q27852316-01484615-5F63-4D9B-A883-CF66F34DCC21

Q27852316-14C60F25-4F5E-4F28-92F8-B18B52EE2E95

Q27852316-1FCA5868-16B1-440F-A08D-770A354050AC

Q27852316-26CF618E-B483-46E1-B83C-B32B29FD779A

Q27852316-2C3FEBAA-4AE5-44D3-847C-D81DD89B6CD4

Q27852316-3F9EB697-0AB2-4D95-A58F-4B4074F8D737

Q27852316-61539D48-16FE-42AE-9E41-C522313DC59F

Q27852316-66A5F8B0-3EA7-48DE-9A65-6F35403DC632

Q27852316-715EB001-AB1B-4ED7-90CB-B4E1A1F71DDD

Q27852316-9A12606F-3B5F-4719-AA78-79B18B2EF60D

P304

Q27852316-52CF11D6-2457-4EB0-B3C7-BFA6C37ABDD7

P31

Q27852316-AFD2AE47-BCA3-4B3F-8C07-642BE0BC4C3A

P3181

Q27852316-0ED6E957-9BAF-44AA-85C0-9233C686FC5D

P356

Q27852316-6F6F1CF5-82AE-44DB-92A5-136BED36F240

P407

Q27852316-3F8C4C7A-4146-491E-9FD4-75413394599E

P433

Q27852316-98B377DE-6018-476B-8D41-1374E1DB7499

P478

Q27852316-8A2899BE-BBF0-472A-822E-3A918EF01B44

P50

Q27852316-46C583E4-270C-4B4B-A39B-E7DDECA95B75

Q27852316-694B51A9-51CD-43BB-AFF1-99B77983365A

Q27852316-AFED28E2-B919-447E-B439-10244EA0A14E

Q27852316-F81CDB1E-DCCD-404C-ADB0-D9595A4BE68C

P577

Q27852316-2C44FBFF-FE8A-4934-8E88-9D92B2EA580B

P698

Q27852316-A3CFCBA2-CCBA-4EBC-9807-729D6D74CE72

P921

Q27852316-121AD703-2720-4F35-963F-14B7C9CB1610

Q27852316-36355962-76EE-4FC3-8D1C-6FE73F4FAB82

P3181

P356

P1433

The New England Journal of Medicine

P1476

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer

@en

P2093

Alice T Shaw

http://www.w3.org/2001/XMLSchema#string

Anna Polli

http://www.w3.org/2001/XMLSchema#string

Benjamin Besse

http://www.w3.org/2001/XMLSchema#string

Benjamin J Solomon

http://www.w3.org/2001/XMLSchema#string

D Ross Camidge

http://www.w3.org/2001/XMLSchema#string

Dong-Wan Kim

http://www.w3.org/2001/XMLSchema#string

Gregory J Riely

http://www.w3.org/2001/XMLSchema#string

Kazuhiko Nakagawa

http://www.w3.org/2001/XMLSchema#string

Keith D Wilner

http://www.w3.org/2001/XMLSchema#string

Kenneth J O'Byrne

http://www.w3.org/2001/XMLSchema#string

P304

2385-2394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

8423

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1214886

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

368

http://www.w3.org/2001/XMLSchema#string

P50

Fiona Blackhall

Denis Moro-Sibilot

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23724913

http://www.w3.org/2001/XMLSchema#string

P921